QTGAL

Summary

QTGAL (queuosine-tRNA galactosyltransferase, HGNC:21727) is a protein-coding gene on chromosome 17q25.3, encoding Queuosine-tRNA galactosyltransferase (Q67FW5). Glycosyltransferase that specifically catalyzes galactosylation of cytoplasmic tRNA(Tyr) modified with queuosine at position 34 (queuosine(34)).

Enables tRNA-queuosine(34) galactosyltransferase activity. Involved in regulation of translation and tRNA modification. Is active in cytoplasm.

Source: NCBI Gene 146712 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 242 total — 1 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_001009905

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21727
Approved symbol	QTGAL
Name	queuosine-tRNA galactosyltransferase
Location	17q25.3
Locus type	gene with protein product
Status	Approved
Aliases	B3GNT8
Ensembl gene	ENSG00000175711
Ensembl biotype	protein_coding
OMIM	615337
Entrez	146712

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 8 protein_coding, 4 protein_coding_CDS_not_defined, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000320865, ENST00000570947, ENST00000571218, ENST00000571301, ENST00000571394, ENST00000571954, ENST00000572267, ENST00000572977, ENST00000573363, ENST00000573629, ENST00000576599, ENST00000905888, ENST00000905889, ENST00000905890, ENST00000905891, ENST00000905892, ENST00000915988

RefSeq mRNA: 4 — MANE Select: NM_001009905 NM_001009905, NM_001320742, NM_001320743, NM_001421881

CCDS: CCDS32778, CCDS82232

Canonical transcript exons

ENST00000320865 — 13 exons

Exon	Start	End
ENSE00001463771	83051737	83051770
ENSE00003485394	82957181	82957249
ENSE00003512054	82956695	82956769
ENSE00003562724	82946879	82946983
ENSE00003565858	83048669	83048785
ENSE00003594199	82965651	82965746
ENSE00003597813	82961057	82961181
ENSE00003608638	82957359	82957494
ENSE00003621251	83048471	83048570
ENSE00003621983	83035035	83035099
ENSE00003652301	83014454	83014519
ENSE00003666709	83005115	83005210
ENSE00003922562	82942149	82944049

Expression profiles

Bgee: expression breadth ubiquitous, 135 present calls, max score 90.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.0312 / max 151.2561, expressed in 1451 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
169014	2.2227	1242
169011	1.1822	301
169013	0.3301	145
169012	0.1785	80
169010	0.1178	54

Top tissues by expression

138 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	90.45	gold quality
granulocyte	CL:0000094	84.72	gold quality
right uterine tube	UBERON:0001302	84.38	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.13	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.81	gold quality
monocyte	CL:0000576	83.52	gold quality
thymus	UBERON:0002370	83.40	silver quality
leukocyte	CL:0000738	83.17	gold quality
bone marrow	UBERON:0002371	82.75	gold quality
cortical plate	UBERON:0005343	82.27	gold quality
right ovary	UBERON:0002118	82.02	gold quality
skin of leg	UBERON:0001511	81.99	gold quality
zone of skin	UBERON:0000014	81.66	gold quality
skin of abdomen	UBERON:0001416	81.25	gold quality
sural nerve	UBERON:0015488	81.21	gold quality
left ovary	UBERON:0002119	81.19	gold quality
spleen	UBERON:0002106	80.86	gold quality
ovary	UBERON:0000992	80.70	gold quality
right hemisphere of cerebellum	UBERON:0014890	80.70	gold quality
left uterine tube	UBERON:0001303	80.39	gold quality
hindlimb stylopod muscle	UBERON:0004252	80.33	gold quality
cerebellum	UBERON:0002037	80.20	gold quality
cerebellar hemisphere	UBERON:0002245	80.20	gold quality
cerebellar cortex	UBERON:0002129	80.18	gold quality
endocervix	UBERON:0000458	80.15	gold quality
ectocervix	UBERON:0012249	79.40	gold quality
body of uterus	UBERON:0009853	79.32	gold quality
pituitary gland	UBERON:0000007	79.27	gold quality
primary visual cortex	UBERON:0002436	79.25	gold quality
stromal cell of endometrium	CL:0002255	79.14	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

58 targeting QTGAL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4719	99.73	72.10	3329
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-657	99.48	66.02	848
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6088	99.29	68.45	1284
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-3606-3P	99.11	69.84	3254

Literature-anchored findings (GeneRIF, showing 1)

• beta3-GnTL1 is similar to beta1, 3-N-acetylglucosaminyltransferase (PMID:15560372)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	b3gntl1	ENSDARG00000043431
mus_musculus	B3gntl1	ENSMUSG00000046605
rattus_norvegicus	B3gntl1	ENSRNOG00000049724
caenorhabditis_elegans	F13G3.6	WBGENE00008766

Protein

Protein identifiers

Queuosine-tRNA galactosyltransferase — Q67FW5 (reviewed: Q67FW5)

Alternative names: Beta-1,3-N-acetylglucosaminyltransferase 8, UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like protein 1

All UniProt accessions (4): Q67FW5, I3L1A1, I3L232, I3L4B6

UniProt curated annotations — full annotation on UniProt →

Function. Glycosyltransferase that specifically catalyzes galactosylation of cytoplasmic tRNA(Tyr) modified with queuosine at position 34 (queuosine(34)). Galactosylates the cyclopentene hydroxyl group of queuosine(34) in tRNA(Tyr) to form galactosyl-queuosine(34). Mannosylation of queuosine(34) in tRNA(Tyr) is required to slow-down elongation at cognate codons UAC and suppress stop codon readthrough, thereby regulating protein translation.

Subcellular location. Cytoplasm.

Tissue specificity. Widely expressed. Highly expressed in adult pancreas. Expressed at moderate level in kidney, spleen, thymus, prostate, testis and ovary. Weakly expressed in small intestine, colon, peripheral blood leukocyte and liver.

Similarity. Belongs to the glycosyltransferase 2 family.

RefSeq proteins (4): NP_001009905, NP_001307671, NP_001307672, NP_001408810 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001173	Glyco_trans_2-like	Domain
IPR029044	Nucleotide-diphossugar_trans	Homologous_superfamily

Pfam: PF00535

Catalyzed reactions (Rhea), 1 shown:

• queuosine(34) in tRNA(Tyr) + UDP-alpha-D-galactose = O-5’’-beta-D-galactosylqueuosine(34) in tRNA(Tyr) + UDP + H(+) (RHEA:78231)

UniProt features (2 total): chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q67FW5-F1	96.05	0.92

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-913709	O-linked glycosylation of mucins

MSigDB gene sets: 230 (showing top): GOBP_TRNA_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_AMINOGLYCAN_BIOSYNTHETIC_PROCESS, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, GOBP_RNA_MODIFICATION, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GOBP_AMINOGLYCAN_METABOLIC_PROCESS, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_UP, BOYLAN_MULTIPLE_MYELOMA_C_CLUSTER_UP, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_TRNA_PROCESSING, GOBP_TRNA_MODIFICATION, GOBP_REGULATION_OF_TRANSLATION, GOMF_HEXOSYLTRANSFERASE_ACTIVITY

GO Biological Process (3): tRNA wobble guanine modification (GO:0002099), tRNA modification (GO:0006400), regulation of translation (GO:0006417)

GO Molecular Function (4): tRNA-queuosine(34) galactosyltransferase activity (GO:0141125), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757), hexosyltransferase activity (GO:0016758)

GO Cellular Component (1): cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
O-linked glycosylation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
tRNA wobble base modification	1
tRNA processing	1
RNA modification	1
translation	1
post-transcriptional regulation of gene expression	1
regulation of protein metabolic process	1
UDP-galactosyltransferase activity	1
catalytic activity, acting on a tRNA	1
catalytic activity	1
transferase activity	1
glycosyltransferase activity	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

324 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
QTGAL	TBCD	Q9BTW9	523
QTGAL	FN3KRP	Q9HA64	461
QTGAL	METRNL	Q641Q3	455
QTGAL	FARSA	Q9Y285	439
QTGAL	ALG3	Q92685	411
QTGAL	NOC4L	Q9BVI4	397
QTGAL	TRNAU1AP	Q9NX07	383
QTGAL	DOK6	Q6PKX4	370
QTGAL	NKAIN2	Q5VXU1	360
QTGAL	FGD5	Q6ZNL6	344
QTGAL	EFHB	Q8N7U6	339
QTGAL	IPO4	Q8TEX9	339
QTGAL	PUS7	Q96PZ0	339
QTGAL	TACSTD2	P09758	327
QTGAL	CCT4	P50991	325

IntAct

8 interactions, top by confidence:

A	B	Type	Score
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
IMPDH1	LCMT2	psi-mi:“MI:0914”(association)	0.350
FTL	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
IMPDH1	MGST3	psi-mi:“MI:0914”(association)	0.350
MPP3	B3GNTL1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (5): B3GNTL1 (Affinity Capture-MS), B3GNTL1 (Affinity Capture-RNA), B3GNTL1 (Affinity Capture-MS), B3GNTL1 (Affinity Capture-MS), B3GNTL1 (Affinity Capture-RNA)

ESM2 similar proteins: A2VE14, A5PLN9, B1WC68, D3Z7P3, O54865, O89050, O94925, P13264, P16068, P20595, P38024, P51583, P97834, Q02153, Q0VCB2, Q0VCJ8, Q13042, Q13098, Q3TIR1, Q4R4U1, Q4ZHR9, Q5F450, Q5M887, Q5NVN7, Q5R5F8, Q5RB35, Q5RB59, Q5RBN9, Q5RKN4, Q5ZJB7, Q5ZMH6, Q67FW5, Q6AXQ0, Q6NRT5, Q86TJ2, Q8R349, Q8VH37, Q91YQ7, Q99LD4, Q99PV3

Diamond homologs: A0A0H2URH7, A0A0H3JPC6, A0A0H3JVA1, A1KMV1, A5U6W5, B5L3F2, D4GYG7, D4GYH2, E0U4V7, H2K893, O06483, O32268, P0A5A0, P26401, P47271, P74165, P75086, P9WMX6, P9WMX7, Q07755, Q077R2, Q0P9C6, Q15JF5, Q46632, Q48214, Q48215, Q4V9J0, Q54J42, Q57022, Q67FW5, Q6GV29, Q7BLV3, Q8L0V4, Q8U4M3, Q9CMP0, Q9DB25, Q9LM93, Q9Y673, A0A0H2UR96, A0A0H3JNB0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

242 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	160
Likely benign	30
Benign	15

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
3248403	NC_000019.9:g.(?41916522)(41932683_?)del	Pathogenic
148281	GRCh38/hg38 17q25.3(chr17:82072338-83102552)x1	Likely pathogenic
1707631	GRCh37/hg19 17q25.3(chr17:80509676-81162701)x3	Likely pathogenic

SpliceAI

4403 predictions. Top by Δscore:

Variant	Effect	Δscore
17:82957354:CTCA:C	donor_loss	1.0000
17:82957355:TCACC:T	donor_loss	1.0000
17:82957356:CACCT:C	donor_loss	1.0000
17:82957357:A:AC	donor_gain	1.0000
17:82957357:AC:A	donor_gain	1.0000
17:82957357:ACC:A	donor_loss	1.0000
17:82957358:C:CC	donor_gain	1.0000
17:82957358:CC:C	donor_gain	1.0000
17:82957358:CCTTG:C	donor_gain	1.0000
17:82957491:CGTC:C	acceptor_gain	1.0000
17:82957493:TC:T	acceptor_gain	1.0000
17:82957494:CC:C	acceptor_gain	1.0000
17:82957495:C:CC	acceptor_gain	1.0000
17:82957495:CTGCG:C	acceptor_loss	1.0000
17:82957496:T:C	acceptor_loss	1.0000
17:82957499:G:T	acceptor_gain	1.0000
17:82961053:TCACT:T	donor_loss	1.0000
17:82961054:CA:C	donor_loss	1.0000
17:82961055:A:AC	donor_gain	1.0000
17:82961056:C:CT	donor_gain	1.0000
17:82961056:C:T	donor_loss	1.0000
17:82961056:CT:C	donor_gain	1.0000
17:82961178:CGCC:C	acceptor_gain	1.0000
17:82961179:GCCC:G	acceptor_loss	1.0000
17:82961180:CC:C	acceptor_gain	1.0000
17:82961180:CCCTG:C	acceptor_loss	1.0000
17:82961181:CC:C	acceptor_gain	1.0000
17:82961181:CCTGC:C	acceptor_loss	1.0000
17:82961183:T:A	acceptor_loss	1.0000
17:83014448:ACTT:A	donor_loss	1.0000

AlphaMissense

2371 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:83035065:G:C	S104R	0.990
17:83035065:G:T	S104R	0.990
17:83035067:T:G	S104R	0.990
17:82965707:A:G	W182R	0.989
17:82965707:A:T	W182R	0.989
17:82957421:A:G	W267R	0.985
17:82957421:A:T	W267R	0.985
17:83035086:T:A	K97N	0.984
17:83035086:T:G	K97N	0.984
17:83035049:A:G	C110R	0.980
17:82956704:G:C	C332W	0.976
17:82961168:T:A	D205V	0.976
17:82961168:T:G	D205A	0.976
17:83035047:G:C	C110W	0.976
17:82956711:A:T	V330D	0.974
17:82961169:C:G	D205H	0.973
17:83048672:A:C	S58R	0.973
17:83048672:A:T	S58R	0.973
17:83048674:T:G	S58R	0.973
17:83048684:G:C	F54L	0.973
17:83048684:G:T	F54L	0.973
17:83048686:A:G	F54L	0.973
17:82957403:C:A	G273W	0.971
17:82957423:A:T	I266N	0.971
17:83005201:A:G	C140R	0.971
17:83035079:C:G	A100P	0.971
17:83035044:A:C	F111L	0.970
17:83035044:A:T	F111L	0.970
17:83035046:A:G	F111L	0.970
17:82956705:C:T	C332Y	0.968

dbSNP variants (sampled 300 via entrez): RS1000033274 (17:82957982 C>T), RS1000051607 (17:83051181 G>A,C), RS1000085324 (17:82957814 G>A), RS1000105996 (17:83043263 C>T), RS1000129675 (17:83028925 C>A), RS1000139124 (17:82977195 C>T), RS1000162917 (17:82943656 G>C), RS1000199880 (17:83046853 A>C), RS1000211501 (17:82999619 A>G), RS1000242674 (17:82999455 C>G,T), RS1000256415 (17:82952440 C>T), RS1000291688 (17:83017227 G>A,C), RS1000319733 (17:83046982 C>A), RS1000368694 (17:82947945 C>T), RS1000394901 (17:82965816 T>C)

Disease associations

OMIM: gene MIM:615337 | disease phenotypes: MIM:248600

GenCC curated gene-disease

Mondo (1): maple syrup urine disease (MONDO:0009563)

Orphanet (2): Non-syndromic anorectal malformation (Orphanet:557), Maple syrup urine disease (Orphanet:511)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST006417_9	Plasma factor VII activating protease levels	5.000000e-07
GCST006585_79	Blood protein levels	1.000000e-238
GCST008358_1	Response to cognitive-behavioural therapy in anxiety and major depressive disorders	2.000000e-06
GCST008767_9	Perceived intensity of sucrose	3.000000e-06
GCST010396_22	Gut microbiota (bacterial taxa, hurdle binary method)	2.000000e-06
GCST012033_19	Sleep (1/3-day periodicity)	7.000000e-09
GCST012226_824	Waist circumference adjusted for body mass index	1.000000e-08
GCST012490_207	Femur bone mineral density x serum urate levels interaction	2.000000e-09
GCST90002381_545	Eosinophil count	2.000000e-11
GCST90002388_512	Lymphocyte count	1.000000e-10
GCST90002399_255	Neutrophil percentage of white cells	5.000000e-11
GCST90020029_49	Waist circumference adjusted for body mass index	2.000000e-08

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0007820	cognitive behavioural therapy
EFO:0007874	gut microbiome measurement
EFO:0007789	BMI-adjusted waist circumference
EFO:0004531	urate measurement
EFO:0004842	eosinophil count
EFO:0004587	lymphocyte count
EFO:0007990	neutrophil percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008375	Maple Syrup Urine Disease	C10.228.140.163.100.520; C16.320.565.100.608; C16.320.565.189.520; C18.452.132.100.520; C18.452.648.100.608; C18.452.648.189.520

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, affects cotreatment, increases methylation, decreases expression, increases expression	4
Benzo(a)pyrene	decreases expression, increases methylation	4
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	decreases expression, increases methylation	2
triphenyl phosphate	affects expression	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
ICG 001	decreases expression	1
bisphenol S	decreases methylation, affects cotreatment	1
jinfukang	affects cotreatment, increases expression	1
(+)-JQ1 compound	increases expression	1
Temozolomide	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation, decreases methylation	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Cisplatin	affects cotreatment, increases expression	1
Methapyrilene	decreases methylation	1
Ozone	affects expression, increases abundance	1
Quercetin	decreases expression	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Thiram	decreases expression	1
Valproic Acid	increases methylation	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	decreases expression	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01529060	PHASE2/PHASE3	COMPLETED	Phenylbutyrate Therapy for Maple Syrup Urine Disease
NCT03655223	Not specified	ENROLLING_BY_INVITATION	Early Check: Expanded Screening in Newborns
NCT04248062	Not specified	COMPLETED	Patient and Observer Reported Outcome Measurements in Inborn Errors of Metabolism
NCT04602325	Not specified	RECRUITING	Systemic Biomarkers of Brain Injury From Hyperammonemia
NCT04828863	Not specified	COMPLETED	Neurocognitive Outcomes and Quality of Life in Adults With Maple Syrup Urine Disease (MSUD)
NCT05051657	Not specified	COMPLETED	Evaluation of the Express Plus Range
NCT05687474	Not specified	COMPLETED	Baby Detect : Genomic Newborn Screening
NCT05910151	Not specified	UNKNOWN	Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan
NCT06298292	Not specified	NOT_YET_RECRUITING	Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies
NCT06581991	Not specified	NOT_YET_RECRUITING	Liquid Valine and Isoleucine in Maple Syrup Urine Disease
NCT06664840	Not specified	NOT_YET_RECRUITING	MyRareDiet A Novel Diet Tracking Tool